NCT04717154View on ClinicalTrials.gov

Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

January 19, 2021

Primary Completion Date

August 15, 2024

Study Completion Date

February 15, 2026

Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
BIOLOGICAL

Ipilimumab

4 courses of 1mg/kg q3w

BIOLOGICAL

Nivolumab

4 courses of 3mg/kg q3w, followed by maintenance flat dose (480mg, q4w, for 10 doses)

Trial Locations (1)

6525GA

Radboudumc, Nijmegen

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT04717154 - Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer | Biotech Hunter | Biotech Hunter